Skip to content
Conditions & Health

NAFLD (non-alcoholic fatty liver disease)

Accumulation of fat in the liver not caused by alcohol consumption, affecting up to 30% of adults. Can progress to MASH (inflammatory liver damage). GLP-1 agonists and survodutide show promise in reducing liver fat.

Frequently Asked Questions

What is NAFLD (non-alcoholic fatty liver disease)?
Accumulation of fat in the liver not caused by alcohol consumption, affecting up to 30% of adults. Can progress to MASH (inflammatory liver damage). GLP-1 agonists and survodutide show promise in reducing liver fat.
Why is NAFLD (non-alcoholic fatty liver disease) important in peptide research?
Understanding nafld (non-alcoholic fatty liver disease) is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.

Related Terms

MASH

Metabolic dysfunction-associated steatohepatitis (formerly NASH). Inflammatory liver disease with fat accumulation, hepatocyte damage, and fibrosis risk. Survodutide and semaglutide are in trials for MASH treatment.

Metabolic syndrome

A cluster of conditions including central obesity, elevated blood sugar, high blood pressure, and abnormal cholesterol that together increase the risk of heart disease, stroke, and type 2 diabetes.

Insulin resistance

A condition where cells respond poorly to insulin, requiring the pancreas to produce more insulin to maintain normal blood sugar. A precursor to type 2 diabetes. GLP-1 agonists improve insulin sensitivity.

Related Peptide Profiles

Semaglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.

Survodutide

An investigational dual glucagon/GLP-1 receptor agonist in development for obesity and metabolic liver disease (MASH).

← Back to full glossary